Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)
Zhytomyr Regional Oncology Center ( Site 1515)(0.0 mi away)Contact
+131 other location
triple negative breast cancer
The purpose of this study is to compare the efficacy of olaparib (MK-7339) plus pembrolizumab
(MK-3475) with chemotherapy plus pembrolizumab after induction with first-line chemotherapy
plus pembrolizumab in triple negative breast cancer (TNBC). The primary hypotheses are:
Olaparib plus pembrolizumab prolongs progression-free survival (PFS) compared with
chemotherapy plus pembrolizumab.
Olaparib plus pembrolizumab is non-inferior to chemotherapy plus pembrolizumab in terms
of overall survival (OS).
Olaparib plus pembrolizumab prolongs OS compared with chemotherapy plus pembrolizumab.
Diet and Nutrition,
Chronic Shoulder Pain,
Adverse Effects, Drugs,
Breast Cancer - HER2 Positive,
Near-Sighted Corrective Surgery,
Peripheral Arterial Occlusive Disease,
Triple Negative Breast Cancer,
Triple Negative Breast Neoplasms,
Recurrent Respiratory Papillomatosis,
Razor Bumps (Pseudofolliculitis Barbae),
Metastatic Triple-Negative Breast Cancer
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.